Primjena rendgenskog zračenja u svrhu prevencije transfuzijom uzrokovane reakcije presatka protiv primatelja

Autor(i)

  • Željka Lubina Hrvatski Zavod za Transfuzijsku Medicinu image/svg+xml Autor
  • Matea Vinković Hrvatski Zavod za Transfuzijsku Medicinu image/svg+xml Autor
  • Maja Strauss Patko Hrvatski Zavod za Transfuzijsku Medicinu image/svg+xml Autor
  • Irena Jukić Hrvatski Zavod za Transfuzijsku Medicinu image/svg+xml Autor

DOI:

https://doi.org/10.55378/rv.46.1.4

Ključne riječi:

reakcija presatka protiv primatelja uzrokovana transfuzijom, ozračivači krvi, vijabilni limfociti, krvni pripravci, rendgensko zračenje

Sažetak

Transfuzijom uzrokovana reakcija presatka protiv primatelja (TA-GvHD) je rijetka komplikacija transfuzijskog liječenja krvnim pripravcima koji sadrže vijabilne limfocite. Rizik za pojavu TA-GvHD-a ovisi o broju i održivosti limfocita u krvnom pripravku, osjetljivosti imunološkog sustava primatelja i stupnju imunološke razlike u sustavu humanog leukocitnog antigena (eng. human leukocyte antigen, HLA) između darivatelja i primatelja krvnog pripravka.

Standardna metoda kojom se uspješno prevenira TA-GvHD je ozračivanje krvnih pripravaka ionizirajućim zračenjem apsorbiranom dozom zračenja 25-50 Gy. Cilj ozračivanja je inaktivacija vijabilnih limfocita prisutnih u staničnom krvnom pripravku (eritrociti, trombociti, leukociti) i inhibicija njihove proliferacije u primatelja krvnog pripravka.

U zadnjih dvadesetak godina sve se više napušta ozračivanje krvnih pripravaka gama zračenjem i zamjenjuje se ozračivanjem rendgenskim zračenjem pomoću posebno konstruiranih kabinetskih uređaja koji su naročito pogodni za rad u bolnicama i bankama krvi. Time se smanjuje rizik od slučajne ili namjerne zlouporabe radioaktivnog izvora, rješava problem zbrinjavanja radioaktivnog otpada te smanjuje izloženost djelatnika ionizirajućem zračenju u ustanovama koje se bave ozračivanjem krvnih pripravaka.

U Banci krvi Hrvatskog zavoda za transfuzijsku medicinu ozračivanje krvnih pripravaka rendgenskim zračenjem provodi se od 2014. godine i godišnje se ozrači oko 20.000 staničnih krvnih pripravaka za potrebe transfuzijskog liječenja bolesnika s rizikom za razvoj TA-GvHD-a.

Reference

Shimoda T. On postoperative erythroderma (In Japanese). Geka 1955; 17: 487-492

Mathe G, Bernard J, De VM, Schwarzenberg L, Larrieu MJ, Lalanne CM. New trials with homologous bone marrow grafts after total irradiation in children with acute leukemia in remission. The problem of the secondary syndrome in man. Rev Hematol. 1960;15:115–61.

Barnes DW, Loutit JF, Micklem HS. „Secondary disease“ of radiation chimeras: a syndrome due to lymphoid aplasia. Ann N Y Acad Sci [Internet]. 1962;99:374–85. Available from: http://dx.doi.org/10.1111/j.1749-6632.1962.tb45321.x

Hathaway WE, Brangle RW, Nelson TL, Roeckel IE. Aplastic anemia and alymphocytosis in an infant with hypogammaglobulinemia: Graftvs-host reaction? J Pediatr. 1966;68:713–22.

Billingham RE. The biology of graft-vs-host reactions. Harvey Lect 1966; 67:62:21–78.

Aoki Y, Nakamura H, Sakakibara Y. Probable graft-versus-host reaction following massive blood transfusion in an aged patient with postoperative aortic aneurysm: a case report. Nihon Naika Gakkai Zasshi [Internet]. 1984;73(8):1209–16. Available from: http://dx.doi.org/10.2169/naika.73.1209

Thaler M, Shamiss A, Orgad S, Huszar M, Nussinovitch N, Meisel S, et al. The role of blood from HLA-homozygous donors in fatal transfusion-associated graft-versus-host disease after open-heart surgery. N Engl J Med [Internet]. 1989;321(1):25–8. Available from: http://dx.doi.org/10.1056/NEJM198907063210105

Schroeder ML. Transfusion-associated graft-versus-host disease: Review. Br J Haematol [Internet]. 2002;117(2):275–87. Available from: http://dx.doi.org/10.1046/j.1365-2141.2002.03450.x

Nishimura M, Hidaka N, Akaza T, Tadokoro K, Juji T. Immunosuppressive efects of chloroquine: potential effectivness for treatment of posttransfusion graft-versus-host disease. Transfus Med. 1998;8:209–14.

Przepiorka D, Kernan NA. Ippoliti i sur. Daclizumab, a humanized antiinterleukin-2 receptor alpha chain antibody, for treatment of acute graftversus-host disease. Blood. 2000;95:83–9.

Yasukawa M, Shinozaki F, Hato T, Takada K, Ishii Y, Tamai T, et al. Successful treatment of transfusion-associated graft-versus-host disease. Br J Haematol [Internet]. 1994;86(4):831–6. Available from: http://dx.doi.org/10.1111/j.1365-2141.1994.tb04838.x

Prince M, Szer J, van der Weyden MB, Pedersen JS, Holdsworth RF, Whyte G. Transfusion associated graft-versus-host disease after cardiac surgery: response to antithymocyte-globulin and corticosteroid therapy. Aust N Z J Med [Internet]. 1991;21(1):43–6. Available from: http://dx.doi.org/10.1111/j.1445-5994.1991.tb03000.x

Uchida S, Tadokoro K, Takahashi M, Yahagi H, Satake M, Juji T. Analysis of 66 patients definitive with transfusion-associated graft-versus-host disease and the effect of universal irradiation of blood: Analysis of patients definitive with TA-GVHD. Transfus Med [Internet]. 2013;23(6):416–22. Available from: http://dx.doi.org/10.1111/tme.12081

Cole LJ, Garver RM. Abrogation by injected mouse blood of protective effect of foreign bone marrow in lethally X-irradiated mice. Nature [Internet]. 1959;184(4701):1815–6. Available from: http://dx.doi.org/10.1038/1841815a0

Davey RJ. The effect of irradiation on blood components. Baldwin ML, Jefferies LC, editors. Bethesda, MD: American Association of Blood Banks; 1992.

Davey RJ. Transfusion-associated graft-versus-host disease and the irradiation of blood components. Immunol Invest [Internet]. 1995;24(1–2):431–4. Available from: http://dx.doi.org/10.3109/08820139509062791

Badr Eldin A, editor. Modern approaches to quality control. InTech; 2011

Foukaneli T, Kerr P, Bolton-Maggs PHB, Cardigan R, Coles A, Gennery A, et al. Guidelines on the use of irradiated blood components. Br J Haematol [Internet]. 2020;191(5):704–24. Available from: http://dx.doi.org/10.1111/bjh.17015

Blood irradiators [Internet]. Gov.in. [cited 2022 Jan 31]. Available from: https://www.aerb.gov.in/english/regulatory-facilities/radiation-facilities/application-in-medicine/blood-irradiators

Moroff G, Luban NL. The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus Med Rev [Internet]. 1997;11(1):15–26. Available from: https://www.sciencedirect.com/science/article/pii/S0887796397800065

Treleaven J, Gennery A, Marsh J, Norfolk D, Page L, Parker A, et al. Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force: Guidelines. Br J Haematol [Internet]. 2011;152(1):35–51. Available from: http://dx.doi.org/10.1111/j.1365-2141.2010.08444.

Alternative Technologies White Paper (cisa.gov). 2019.

Blood_Irradiation.pdf (nti.org) Alternative Technologies White Paper (cisa.gov). 2019.

Replacing cesium-137 blood irradiators [Internet]. The Nuclear Threat Initiative. 2018 [cited 2022 Jan 31]. Available from: https://www.nti.org/analysis/articles/cesium-137-blood-irradiator-replacement/

Rad Source Technologies, View my complete profile. Rad Source Technologies [Internet]. Blogspot.com. [cited 2022 Jan 31]. Available from: https://radsourcetechnologies.blogspot.com/2010/08/revolutionary-x-ray-tube-design.html

Aboufazeli B, Tamaddoni A, Shabestani Monfared A, Zabihi E, Abedian Z, Mahdavi SR, et al. The evaluation of optimum radiation dose to prevent transfusion-associated graft-versus-host disease among the Iranian population. Iran J Pediatr [Internet]. 2018;28(4). Available from: http://dx.doi.org/10.5812/ijp.62300

Marschner S, Goodrich R. Pathogen reduction technology treatment of Platelets, Plasma and whole blood using riboflavin and UV light. Transfus Med Hemother [Internet]. 2011;38(1):8–18. Available from: http://dx.doi.org/10.1159/000324160

Fda.gov. [cited 2022 Jan 31]. Available from: https://www.fda.gov/media/90594/download

Hosseini E, Kianinodeh F, Ghasemzadeh M. Irradiation of platelets in Transfusion Medicine: risk and benefit judgments. Platelets [Internet]. 2021;1–13. Available from: http://dx.doi.org/10.1080/09537104.2021.1990250

VER Primjena rendgenskog zračenja u svrhu prevencije transfuzijom

Preuzimanja

Objavljeno

03.05.2022

Broj časopisa

Rubrika

Pregledni radovi

Kategorije

Kako citirati

Lubina, Željka, Matea Vinković, Maja Strauss Patko, i Irena Jukić. 2022. „Primjena Rendgenskog zračenja U Svrhu Prevencije Transfuzijom Uzrokovane Reakcije Presatka Protiv Primatelja“. Radiološki Vjesnik 46 (1): 25-30. https://doi.org/10.55378/rv.46.1.4.

Slični članci

1-10 od 27

Također možete Započni napredno pretraživanje sličnosti za ovaj članak.